[go: up one dir, main page]

MX2018006790A - Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos. - Google Patents

Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.

Info

Publication number
MX2018006790A
MX2018006790A MX2018006790A MX2018006790A MX2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A
Authority
MX
Mexico
Prior art keywords
etrahydrouridine
decitabin
compositions containing
tetrahydrouridine
compositions
Prior art date
Application number
MX2018006790A
Other languages
English (en)
Other versions
MX383757B (es
Inventor
Saunthararajah Yogen
Vadivelu Santhosh
Desimone Joseph
Lau Henry
Original Assignee
Epidestiny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidestiny Inc filed Critical Epidestiny Inc
Publication of MX2018006790A publication Critical patent/MX2018006790A/es
Publication of MX383757B publication Critical patent/MX383757B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones que comprenden decitabina y tetrahidrouridina o 5-azacitidina y tetrahidrouridina para el tratamiento del cancer. Las composiciones en forma de pildora se administran a un sujeto humano en secuencia o de manera alternada en funcion de la medicion de biomarcadores predictivos.
MX2018006790A 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos MX383757B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262839P 2015-12-03 2015-12-03
US201662429292P 2016-12-02 2016-12-02
PCT/US2016/064935 WO2017096357A1 (en) 2015-12-03 2016-12-05 Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof

Publications (2)

Publication Number Publication Date
MX2018006790A true MX2018006790A (es) 2019-05-02
MX383757B MX383757B (es) 2025-03-04

Family

ID=58798100

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007569A MX393043B (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos
MX2018006790A MX383757B (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021007569A MX393043B (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos

Country Status (9)

Country Link
US (3) US11376270B2 (es)
EP (2) EP3960182B1 (es)
JP (2) JP7194021B2 (es)
CN (1) CN109789155B (es)
BR (1) BR112018011324A2 (es)
CA (1) CA3007357C (es)
DK (2) DK3383406T3 (es)
MX (2) MX393043B (es)
WO (1) WO2017096357A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020242983A1 (en) 2019-05-24 2020-12-03 The Cleveland Clinic Foundation Timed administration of decitabine and 5-azacytidine for cancer treatment
US20210077492A1 (en) * 2019-09-17 2021-03-18 The Trustees Of Indiana University Methods and compositions of treating pancreatic cancer
WO2021211890A1 (en) * 2020-04-16 2021-10-21 Adimabio Llc Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
DK1156827T3 (da) 1999-03-01 2007-02-05 Halogenetics Inc Anvendelse af sammensætninger omfattende CldC som strålingssensibilisatorer ved behandlingen af neoplastiske sygdomme
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050056280A1 (en) 2002-12-31 2005-03-17 Nektar Therapeutics Receptacle for an aerosolizable pharmaceutical formulation
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7601699B2 (en) 2005-08-01 2009-10-13 Nupotential, Inc. Production of reprogrammed cells with restored potential
EP2205073A4 (en) 2007-09-26 2013-03-06 Sinai School Medicine AZACYTIDINE ANALOGS AND USES THEREOF
EP2050757A1 (en) * 2007-10-10 2009-04-22 Cilag AG Method of producing 2' -deoxy-5-azacytidine (Decitabine)
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP4327888A3 (en) 2008-05-15 2024-05-22 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010075301A1 (en) 2008-12-22 2010-07-01 Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US9265785B2 (en) * 2008-12-22 2016-02-23 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
WO2010093435A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
AR076263A1 (es) 2009-04-06 2011-06-01 Eisai Inc Composiciones y metodos para tratar cancer. uso.
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
WO2010118013A1 (en) 2009-04-06 2010-10-14 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
CN102485232A (zh) * 2010-12-06 2012-06-06 苏州科耐尔医药科技有限公司 一种含地西他滨的药物组合物
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US8426143B2 (en) * 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
US9476099B2 (en) 2012-08-10 2016-10-25 Trustees Of Dartmouth College Method for determining sensitivity to decitabine treatment
US20140100182A1 (en) 2012-10-05 2014-04-10 The Cleveland Clinic Foundation Nanogel-Mediated Drug Delivery
ES2877103T3 (es) 2013-03-15 2021-11-16 Epigenetics Pharma Llc Análogos de pirimidina fluorados y métodos de uso de los mismos
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer

Also Published As

Publication number Publication date
EP3383406B1 (en) 2021-10-20
JP2018538370A (ja) 2018-12-27
EP3383406A4 (en) 2019-08-21
CA3007357A1 (en) 2017-06-08
US20220152075A1 (en) 2022-05-19
CN109789155B (zh) 2025-02-07
DK3383406T3 (da) 2022-01-10
JP7194021B2 (ja) 2022-12-21
US20200246368A1 (en) 2020-08-06
BR112018011324A2 (pt) 2018-12-04
EP3960182A1 (en) 2022-03-02
US11376270B2 (en) 2022-07-05
JP2022184941A (ja) 2022-12-13
MX383757B (es) 2025-03-04
CA3007357C (en) 2023-12-05
EP3383406A1 (en) 2018-10-10
MX393043B (es) 2025-03-24
WO2017096357A1 (en) 2017-06-08
US20240165142A1 (en) 2024-05-23
EP3960182B1 (en) 2025-03-19
MX2021007569A (es) 2022-06-09
DK3960182T3 (da) 2025-04-07
CN109789155A (zh) 2019-05-21
US11779591B2 (en) 2023-10-10

Similar Documents

Publication Publication Date Title
CL2018001384A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
DK3475295T3 (da) Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
ECSP15026557A (es) Compuestos y sus métodos de empleo
UY40513A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de esta
MX383494B (es) Ácidos nucleicos libres de células para el análisis del microbioma humano y componentes del mismo.
MX2017000569A (es) Emulsiones de silicona.
DK3294770T4 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015003704A1 (es) Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer
BR112016026001A2 (pt) Composições de biocerâmica e usos biomoduladores das mesmas
DK3354661T3 (da) Fuldstændigt humant antistof mod human CD137 og anvendelse deraf
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
CL2019000033A1 (es) Variantes de xilanasa y polinucleótidos que las codifican.
CL2016003260A1 (es) Profármacos de gemcitabina
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
DK3795072T3 (da) Intermitterende måling af partialtrykket af en analyt i hudvævet
BR112017013481A2 (pt) material permeável a gás
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
CR20150648A (es) Derivados de nucleósido 4´-azido, 3´-desoxi-3´-fluoro sustituido
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
SMP201600230A1 (it) Composizione cosmetica
SV2018005730A (es) Biomarcadores para copanlisib
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
MX2018006790A (es) Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.